These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 29726480)

  • 21. Sustained nicorandil administration reduces the infarct size in ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention.
    Wang S; Duan Y; Feng X; Liu L; Shi Z; Wang B; Xia C; Man W; Wang H; Zhao Z; Sun D
    Anatol J Cardiol; 2019 Mar; 21(3):163-171. PubMed ID: 30821716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Nicorandil Administration on Infarct Size in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial.
    Qian G; Zhang Y; Dong W; Jiang ZC; Li T; Cheng LQ; Zou YT; Jiang XS; Zhou H; A X; Li P; Chen ML; Su X; Tian JW; Shi B; Li ZZ; Wu YQ; Li YJ; Chen YD
    J Am Heart Assoc; 2022 Sep; 11(18):e026232. PubMed ID: 36073634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of nicorandil on ventricular arrhythmia in patients with acute ST-segment elevation myocardial infarction underwent emergent percutaneous coronary intervention treatment].
    Wang YP; Zhang Y; Sun YR; Sun ZG; Zuo ZK; Feng ZR; Chang FY; Xu YC; Chen BZ; Ye YY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Aug; 45(8):701-705. PubMed ID: 28851188
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial.
    Choe JC; Oh JH; Lee HC; Lee JW; Park TS; Park JH; Kim E; Kim MS; Ahn J; Park JS; Lee HW; Choi JH; Cha KS
    Acta Cardiol; 2023 Oct; 78(8):880-888. PubMed ID: 36942830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction.
    Geng W; Zhang Q; Liu J; Tian X; Zhen L; Song D; Yang Y; Meng H; Wang Y; Chen J
    J Interv Cardiol; 2018 Apr; 31(2):136-143. PubMed ID: 29171086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of NT-proBNP on admission for early risk stratification of patients undergoing primary percutaneous coronary intervention.
    Ayhan E; Isık T; Uyarel H; Ergelen M; Cicek G; Ozyurtlu F; Ghannadian B; Tanboga IH
    Kardiol Pol; 2013; 71(2):165-75. PubMed ID: 23575711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction.
    Pan W; Wang LF; Yu JH; Fan Y; Yang SS; Zhou LJ; Li Y; Li WM
    Chin Med J (Engl); 2009 Nov; 122(22):2718-23. PubMed ID: 19951602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Quisi A; Alıcı G
    J Clin Lab Anal; 2018 Nov; 32(9):e22598. PubMed ID: 29943408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention.
    Topuz M; Oz F; Akkus O; Sen O; Topuz AN; Bulut A; Ozbicer S; Okar S; Koc M; Gur M
    Perfusion; 2017 Apr; 32(3):206-213. PubMed ID: 27770057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of intracoronary verapamil versus sodium nitroprusside for the prevention of microvascular obstruction during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Abdelaziz HK; Elkilany W; Khalid S; Sabet S; Saad M
    Coron Artery Dis; 2017 Jan; 28(1):11-16. PubMed ID: 27556348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0.
    Kai T; Oka S; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
    Circ J; 2021 Sep; 85(10):1770-1778. PubMed ID: 34305099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aggarwal P; Rekwal L; Sinha SK; Nath RK; Khanra D; Singh AP
    Ann Cardiol Angeiol (Paris); 2021 Jun; 70(3):136-142. PubMed ID: 33962782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of intracoronary injection with xuesaitong in treating post-PCI slow-reflow phenomenon in patients with ST-segment elevation myocardial infarction].
    Gan LJ; Zhang CH; Zhang M
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Apr; 30(4):348-51. PubMed ID: 20669666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D level predicts angiographic no-reflow phenomenon after percutaneous coronary intervention in patients with ST segment elevation myocardial infarction.
    Şen Ö; Şen SB; Topuz AN; Topuz M
    Biomark Med; 2021 Oct; 15(15):1357-1366. PubMed ID: 34533051
    [No Abstract]   [Full Text] [Related]  

  • 35. Association between clinical parameters and ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction.
    Unikas R; Budrys P
    Medicina (Kaunas); 2016; 52(3):156-62. PubMed ID: 27496185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy study of prourokinase injection during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction.
    Jiang W; Xiong X; Du X; Ma H; Li W; Cheng F
    Coron Artery Dis; 2021 Jan; 32(1):25-30. PubMed ID: 32310850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of serum cystatin C levels with myocardial perfusion and cardiac functional recovery in patients with anterior wall ST elevation myocardial infarction treated with primary coronary intervention.
    Tang L; Fang ZF; Zhou SH; Tai S; Ahmed S; Huang F; Shen XQ; Zhao YS; Hu XQ
    Heart Vessels; 2016 Sep; 31(9):1456-66. PubMed ID: 26498756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of intracoronary adenosine before stenting for the prevention of no-reflow in patients with ST-elevation myocardial infarction.
    Sadeghian M; Mousavi SH; Aamaraee Z; Shafiee A
    Scand Cardiovasc J; 2022 Dec; 56(1):23-27. PubMed ID: 35253571
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina.
    Hwang J; Lee HC; Kim BW; Yang MJ; Park JS; Park JH; Lee HW; Oh J; Choi JH; Cha KS; Hong TJ; Song S; Kim SP
    J Cardiol; 2013 Aug; 62(2):77-81. PubMed ID: 23731922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of No-Reflow Phenomenon in Young Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Celik T; Balta S; Ozturk C; Kaya MG; Aparci M; Yildirim OA; Demir M; Unlu M; Demirkol S; Kilic S; Iyisoy A
    Angiology; 2016 Aug; 67(7):683-9. PubMed ID: 26369341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.